Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02593708
Title Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Michelle Melisko

Advanced Solid Tumor


Neratinib + Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.